Health
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis ","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability ","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":215,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis.","length":427,"tagName":"p"},{"type":"text","content":""As a leader in gastroenterology, AbbVie remains focused on advancing the understanding of IBD and helping raise the standard of care through scientific innovation and a broad portfolio of marketed and investigational therapies," said Andrew Anisfeld, Ph.D., vice president, global medical affairs, immunology, AbbVie. "Our research presented at DDW adds to the growing body of evidence demonstrating the sustained durability of clinical and endoscopic response, as well as the established safety profile, of risankizumab and upadacitinib for people living with IBD."","length":587,"tagName":"p"},{"type":"text","content":"Real-World Data for Patients on Risankizumab in Crohn's Disease ","length":67,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sustained symptom relief and reduced need for concomitant therapy: A 52-week follow-up of adults with moderately to severely active Crohn's disease treated with risankizumab from the ASPIRE-CD study showed rapid and sustained improvements in abdominal pain, bowel urgency and liquid/soft stools. Among patients with extraintestinal manifestations of arthritis and skin conditions, 25% and 46%, respectively, reported experiencing relief at Week 52. By Week 52, the use of corticosteroids decreased from 34% at baseline to 7%, and over-the-counter therapies had decreased from 72% at baseline to 49%.","length":608,"tagName":"p"}]}],"tagName":"...